flucytosine has been researched along with Glial Cell Tumors in 46 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5FC, 5-fluorocytosineBBB, Basso, Beattie, and BresnahanCD, cytosine deaminaseDP, diastolic blood pressureGCV, ganciclovir; hNSCs, human neural stem cellsISCG, intramedullary spinal cord gliomasMAP, mean arterial blood pressureNSCs, neural stem cellsSP, systolic blood pressureTK, thymidine kinase." | 3.83 | Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. ( Abd-El-Barr, M; Aljuboori, Z; Anderson, JE; Chi, JH; Han, I; Haragopal, H; Kim, SU; Lee, HJ; Ropper, AE; Sidman, RL; Snyder, EY; Teng, YD; Viapiano, MS; Zeng, X, 2016) |
| "Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors." | 3.72 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003) |
| "In this study, we investigated the feasibility of a double-suicide gene/prodrug therapy, involving direct introduction of the herpes simplex virus Type 1 thymidine kinase (TK) gene and the Escherichia coli cytosine deaminase (CD) gene, via a recombinant adenoviral vector, and ganciclovir (GCV) and/or 5-fluorocytosine (5-FC) treatment, in a rat C6 glioma model." | 3.70 | Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. ( Chang, JW; Chung, SS; Kim, E; Kim, JH; Lee, H; Lee, Y, 2000) |
| "Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults." | 2.61 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019) |
| "High-grade gliomas are extremely difficult to treat because they are invasive and therefore not curable by surgical resection; the toxicity of current chemo- and radiation therapies limits the doses that can be used." | 1.39 | Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. ( Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV, 2013) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP." | 1.38 | Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. ( Date, I; Hamada, H; Ichikawa, T; Inoue, S; Kambara, H; Kosaka, H; Kurozumi, K; Maruo, T; Nakamura, K, 2012) |
| "Medulloblastomas are highly malignant neuroectodermal cerebellar tumors of children." | 1.34 | Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. ( Bang, JH; Fujii, M; Ito, M; Ito, S; Kim, SU; Natsume, A; Park, IH; Shimato, S; Takeuchi, H; Wakabayashi, T; Yoshida, J, 2007) |
| "The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS." | 1.33 | Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006) |
| "Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC." | 1.31 | In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. ( Adachi, Y; Furuta, T; Hamada, H; Ichikawa, T; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T; Yoshida, Y, 2000) |
| " New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules." | 1.31 | Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. ( Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000) |
| " In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells." | 1.27 | Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 4 (8.70) | 18.2507 |
| 2000's | 17 (36.96) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH | 1 |
| Sun, JM | 1 |
| Chen, BM | 1 |
| Lin, SC | 1 |
| Chang, HF | 1 |
| Collins, S | 1 |
| Chang, D | 1 |
| Wu, SF | 1 |
| Lu, YC | 1 |
| Wang, W | 2 |
| Chen, TC | 3 |
| Kasahara, N | 9 |
| Wang, HE | 1 |
| Tai, CK | 3 |
| Accomando, WP | 1 |
| Rao, AR | 2 |
| Hogan, DJ | 4 |
| Newman, AM | 1 |
| Nakao, A | 1 |
| Alizadeh, AA | 1 |
| Diehn, M | 1 |
| Diago, OR | 4 |
| Gammon, D | 4 |
| Haghighi, A | 2 |
| Gruber, HE | 8 |
| Jolly, DJ | 8 |
| Ostertag, D | 7 |
| Cloughesy, TF | 3 |
| Petrecca, K | 1 |
| Walbert, T | 3 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 2 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 1 |
| Piccioni, D | 3 |
| Landolfi, J | 3 |
| Chen, CC | 3 |
| Gruber, H | 1 |
| Hogan, D | 1 |
| Accomando, W | 2 |
| Montellano, TT | 1 |
| Kheoh, T | 2 |
| Kabbinavar, F | 1 |
| Vogelbaum, MA | 3 |
| Mitchell, LA | 1 |
| Lopez Espinoza, F | 2 |
| Mendoza, D | 1 |
| Kato, Y | 1 |
| Inagaki, A | 1 |
| Hiraoka, K | 1 |
| Robbins, JM | 5 |
| Elder, JB | 2 |
| Bloomfield, S | 2 |
| Carter, B | 2 |
| Kalkanis, SN | 2 |
| Kesari, S | 2 |
| Lai, A | 2 |
| Lee, IY | 2 |
| Liau, LM | 2 |
| Mikkelsen, T | 2 |
| Nghiemphu, P | 1 |
| Das, A | 3 |
| Lu, G | 1 |
| Carvalho, LA | 1 |
| Teng, J | 1 |
| Fleming, RL | 1 |
| Tabet, EI | 1 |
| Zinter, M | 1 |
| de Melo Reis, RA | 1 |
| Tannous, BA | 1 |
| Sun, CH | 2 |
| Berg, K | 2 |
| Hirschberg, H | 2 |
| Philbrick, BD | 1 |
| Adamson, DC | 1 |
| Aboody, KS | 1 |
| Najbauer, J | 1 |
| Metz, MZ | 1 |
| D'Apuzzo, M | 1 |
| Gutova, M | 1 |
| Annala, AJ | 1 |
| Synold, TW | 1 |
| Couture, LA | 1 |
| Blanchard, S | 1 |
| Moats, RA | 1 |
| Garcia, E | 1 |
| Aramburo, S | 1 |
| Valenzuela, VV | 1 |
| Frank, RT | 1 |
| Barish, ME | 1 |
| Brown, CE | 1 |
| Kim, SU | 4 |
| Badie, B | 1 |
| Portnow, J | 1 |
| Yin, D | 1 |
| Zhai, Y | 1 |
| Ibanez, CE | 3 |
| Kells, AP | 1 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 1 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Wang, F | 1 |
| Zamora, G | 1 |
| Trinidad, A | 1 |
| Chun, C | 1 |
| Kwon, YJ | 1 |
| Madsen, SJ | 1 |
| Huang, TT | 1 |
| Parab, S | 1 |
| Burnett, R | 2 |
| Diago, O | 1 |
| Hofman, FM | 1 |
| Espinoza, FL | 1 |
| Martin, B | 2 |
| Pertschuk, D | 1 |
| Ropper, AE | 1 |
| Zeng, X | 1 |
| Haragopal, H | 1 |
| Anderson, JE | 1 |
| Aljuboori, Z | 1 |
| Han, I | 1 |
| Abd-El-Barr, M | 1 |
| Lee, HJ | 1 |
| Sidman, RL | 1 |
| Snyder, EY | 1 |
| Viapiano, MS | 1 |
| Chi, JH | 1 |
| Teng, YD | 1 |
| Nghiemphu, PL | 1 |
| Chu, A | 1 |
| Hanna, M | 1 |
| McCarthy, D | 1 |
| Mitchell, L | 1 |
| Rodriguez-Aguirre, M | 1 |
| Chung, T | 1 |
| Na, J | 1 |
| Kim, YI | 2 |
| Chang, DY | 1 |
| Kim, H | 1 |
| Moon, HE | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Chung, JK | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Paek, SH | 1 |
| Youn, H | 1 |
| Strebe, JK | 1 |
| Lubin, JA | 1 |
| Kuo, JS | 1 |
| Lv, SQ | 2 |
| Zhang, KB | 1 |
| Zhang, EE | 1 |
| Gao, FY | 1 |
| Yin, CL | 1 |
| Huang, CJ | 1 |
| He, JQ | 2 |
| Yang, H | 3 |
| Shi, DZ | 1 |
| Hu, WX | 1 |
| Li, LX | 1 |
| Chen, G | 1 |
| Wei, D | 1 |
| Gu, PY | 1 |
| Ito, S | 2 |
| Natsume, A | 2 |
| Shimato, S | 2 |
| Ohno, M | 1 |
| Kato, T | 1 |
| Chansakul, P | 1 |
| Wakabayashi, T | 2 |
| Johnson, AJ | 1 |
| Ardiani, A | 1 |
| Sanchez-Bonilla, M | 1 |
| Black, ME | 2 |
| Amundson, KK | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Daublebsky, V | 1 |
| Hlavaty, J | 1 |
| Gunzburg, W | 1 |
| Fei, S | 1 |
| Qi, X | 1 |
| Kedong, S | 1 |
| Guangchun, J | 1 |
| Jian, L | 1 |
| Wei, Q | 1 |
| Kosaka, H | 1 |
| Ichikawa, T | 3 |
| Kurozumi, K | 2 |
| Kambara, H | 2 |
| Inoue, S | 1 |
| Maruo, T | 1 |
| Nakamura, K | 1 |
| Hamada, H | 3 |
| Date, I | 1 |
| Barresi, V | 1 |
| Belluardo, N | 1 |
| Sipione, S | 1 |
| Mudò, G | 1 |
| Cattaneo, E | 1 |
| Condorelli, DF | 1 |
| Wang, B | 1 |
| Yoshimura, I | 1 |
| Liu, YS | 2 |
| Tamiya, T | 2 |
| Ono, Y | 2 |
| Otsuka, S | 1 |
| Adachi, Y | 2 |
| Ohmoto, T | 2 |
| Fischer, U | 1 |
| Steffens, S | 1 |
| Frank, S | 1 |
| Rainov, NG | 1 |
| Schulze-Osthoff, K | 1 |
| Kramm, CM | 1 |
| Conrad, C | 1 |
| Miller, CR | 1 |
| Ji, Y | 1 |
| Gomez-Manzano, C | 1 |
| Bharara, S | 1 |
| McMurray, JS | 1 |
| Lang, FF | 1 |
| Wong, F | 1 |
| Sawaya, R | 1 |
| Yung, WK | 1 |
| Fueyo, J | 1 |
| Lü, SQ | 1 |
| Wang, WJ | 1 |
| Kershaw, AD | 1 |
| Solly, SK | 1 |
| Klatzmann, D | 1 |
| Kaliberov, SA | 1 |
| Market, JM | 1 |
| Gillespie, GY | 1 |
| Krendelchtchikova, V | 1 |
| Della Manna, D | 1 |
| Sellers, JC | 1 |
| Kaliberova, LN | 1 |
| Buchsbaum, DJ | 1 |
| Takeuchi, H | 1 |
| Fujii, M | 1 |
| Ito, M | 1 |
| Park, IH | 1 |
| Bang, JH | 1 |
| Yoshida, J | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Nishiyama, T | 2 |
| Kawamura, Y | 2 |
| Kawamoto, K | 2 |
| Matsumura, H | 2 |
| Yamamoto, N | 2 |
| Ito, T | 2 |
| Ohyama, A | 2 |
| Katsuragi, T | 2 |
| Sakai, T | 2 |
| Ge, K | 2 |
| Xu, L | 1 |
| Zheng, Z | 1 |
| Xu, D | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Wang, ZH | 2 |
| Samuels, S | 1 |
| Gama Sosa, MA | 1 |
| Kolodny, EH | 2 |
| Xu, LF | 1 |
| Zheng, ZC | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Zagzag, D | 1 |
| Zeng, B | 1 |
| Matsumoto, K | 1 |
| Furuta, T | 1 |
| Yoshida, Y | 1 |
| Stegman, LD | 1 |
| Rehemtulla, A | 1 |
| Hamstra, DA | 1 |
| Rice, DJ | 1 |
| Jonas, SJ | 1 |
| Stout, KL | 1 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Chang, JW | 1 |
| Lee, H | 1 |
| Kim, E | 1 |
| Lee, Y | 1 |
| Chung, SS | 1 |
| Kim, JH | 1 |
| Moriuchi, S | 1 |
| Wolfe, D | 1 |
| Tamura, M | 1 |
| Yoshimine, T | 1 |
| Miura, F | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | ||
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flucytosine and Glial Cell Tumors
| Article | Year |
|---|---|
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi | 2019 |
5 trials available for flucytosine and Glial Cell Tumors
| Article | Year |
|---|---|
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cyt | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu | 2018 |
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucyt | 2018 |
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Topics: Confidence Intervals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Vectors; Glioma; Prodru | 2016 |
40 other studies available for flucytosine and Glial Cell Tumors
| Article | Year |
|---|---|
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Topics: Animals; Aziridines; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli Protein | 2020 |
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model | 2017 |
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
Topics: Administration, Intranasal; Animals; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Topics: Animals; Cell Line; Cytosine Deaminase; Female; Flow Cytometry; Flucytosine; Fluorouracil; Glioma; H | 2013 |
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Topics: Animals; Brain Neoplasms; Convection; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Geneti | 2013 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Glioma; Humans; Mi | 2013 |
Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene.
Topics: Antifungal Agents; Cell Line, Tumor; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosi | 2014 |
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos | 2015 |
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Engineering; Genetic Th | 2016 |
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cytosine Deaminase; Dihydrouracil Dehy | 2016 |
"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.
Topics: Brain Neoplasms; Flucytosine; Glioblastoma; Glioma; Humans | 2016 |
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; DNA Primers; Es | 2009 |
Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma.
Topics: Animals; Antimetabolites; Cell Line; Cytosine Deaminase; Flucytosine; Genetic Therapy; Glioma; Human | 2009 |
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma.
Topics: Animals; Bystander Effect; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flu | 2010 |
Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
Topics: Animals; Artificial Gene Fusion; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Flucy | 2011 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Ther | 2012 |
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cytosine Deaminase; | 2012 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro | 2003 |
Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro.
Topics: Cell Death; Cell Division; Culture Media; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic The | 2003 |
Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus.
Topics: Adenoviridae; Antimetabolites; Apoptosis; Caspase 3; Caspase 9; Caspase Inhibitors; Caspases; Cytoch | 2004 |
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Ganciclovir; Genes, Transgeni | 2005 |
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Topics: Adenoviridae; Adenovirus E1A Proteins; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatog | 2005 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th | 2004 |
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Topics: Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Flucytosine; Genes, Transgenic, Suicide | 2005 |
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep | 2006 |
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy | 2007 |
Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Line; Cell Line, Tumor; Cell Movement; Cisterna Mag | 2007 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine; Cytosine Deaminase; Drug Therapy, Combina | 1982 |
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Drug Resistance, Neop | 1997 |
5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon.
Topics: 3T3 Cells; Animals; Apoptosis; Cytosine Deaminase; DNA; DNA Damage; Drug Synergism; Flucytosine; Gli | 1998 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1996 |
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Survival; Cyto | 1999 |
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain; Brain Neoplasms; Cytosine Deaminase; | 2000 |
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Topics: Animals; Antifungal Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gliom | 2000 |
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Antiviral Agents; Artificial Gene Fusion; Brain Neoplasms; C | 2000 |
Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model.
Topics: Animals; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Ganciclovir; G | 2002 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug | 1985 |